odmj
OncoDaily Medical Journal
ODMJ
3067-6444
OncoDaily Medical Journal
US
5510
10.69690/ODMJ-002-1117-5510
Reviews
Gastric Cancer in Latin America
Hernández-Félix
Jorge Humberto
Departamento de Hematología y Oncología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Departamento de Medicina Interna, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Huitzil-Meléndez
Fidel David
Departamento de Hematología y Oncología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Flores
Emilio Conde
Centro Oncológico Hospital Médica Sur, Mexico City, Mexico
Meneses-Medina
Mónica Isabel
Departamento de Hematología y Oncología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
monica.menesesm@incmnsz.mx
17
11
2025
ODMJ-002-1117-5510
Copyright (c) 2025 OncoDaily Medical Journal
2025
OncoDaily Medical Journal
Emilio Conde Flores
Fidel David Huitzil-Meléndez
Gastric Cancer
Gastric Cancer in Latin America
GI cancer
GI Cancer In Latin America
Jorge Humberto Hernández-Félix
LATAM
Latin America
Mónica Isabel Meneses-Medina
production-ready-file-url
[
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024 Jan–Feb;74(1):12–49.
]
[
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May–Jun;74(3):229–63.
]
[
Porras C, Nodora J, Sexton R, et al. Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701). Cancer Causes Control. 2013 Feb;24(2):209–15.
]
[
González-Pons M, Soto-Salgado M, Sevilla J, et al. Seroprevalence of Helicobacter pylori in Hispanics living in Puerto Rico: a population-based study. Helicobacter. 2018 Feb;23(1):e12453.
]
[
Banydeen R, Rose AM, Martin D, et al. Advancing cancer control through research and cancer registry collaborations in the Caribbean. Cancer Control. 2015 Oct;22(4):520–30.
]
[
Torres J, Lopez L, Lazcano E, et al. Trends in Helicobacter pylori infection and gastric cancer in Mexico. Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1874–7.
]
[
Alvarado-Esquivel C. Seroepidemiology of Helicobacter pylori infection in pregnant women in rural Durango, Mexico. Int J Biomed Sci. 2013;9(4):224–9.
]
[
Takahashi-Kanemitsu A, Knight CT, Hatakeyama M. Molecular anatomy and pathogenic actions of Helicobacter pylori CagA that underpin gastric carcinogenesis. Cell Mol Immunol. 2020 Jan;17(1):50–63.
]
[
Con SA, Takeuchi H, Valerín AL, et al. Diversity of Helicobacter pylori cagA and vacA genes in Costa Rica: its relationship with atrophic gastritis and gastric cancer. Helicobacter. 2007 Oct;12(5):547–52.
]
[
Wu X, Chen L, Cheng J, et al. Effect of dietary salt intake on risk of gastric cancer: a systematic review and meta-analysis of case-control studies. Nutrients. 2022 Oct 12;14(20):4260.
]
[
Pan American Health Organization. Salt intake [Internet]. [cited 2025 Jul 8]. Available from: https://www.paho.org/fr/node/90878
]
[
Guarnieri L, Castronuovo L, Flexner N, et al. Monitoring sodium content in processed and ultraprocessed foods in Argentina 2022: compliance with national legislation and regional targets. Public Health Nutr. 2024 Oct 2;27(1):e193.
]
[
Gutiérrez-Salmeán G, Miranda-Alatriste PV, Benítez-Alday P, et al. Knowledge, attitudes, and behaviors toward salt consumption and its association with 24-hour urinary sodium and potassium excretion in adults living in Mexico City: cross-sectional study. Interact J Med Res. 2024 Nov 18;13:e57265.
]
[
Mill JG, Malta DC, Nilson EAF, et al. Factors associated with salt intake in the Brazilian adult population: National Health Survey. Cien Saude Colet. 2021 Feb;26(2):555–67.
]
[
Margozzini P, Passi Á. Encuesta Nacional de Salud, ENS 2016–2017: un aporte a la planificación sanitaria y políticas públicas en Chile. ARS Med Rev Cienc Med. 2018;43(1):30–4.
]
[
Serafini M, Bellocco R, Wolk A, et al. Total antioxidant potential of fruit and vegetables and risk of gastric cancer. Gastroenterology. 2002 Oct;123(4):985–91.
]
[
Ramírez-Silva I, Rivera JA, Ponce X, et al. Fruit and vegetable intake in the Mexican population: results from the Mexican National Health and Nutrition Survey 2006. Salud Publica Mex. 2009;51(Suppl 4):S574–85.
]
[
Machado RHV, Feferbaum R, Leone C. Fruit intake and obesity: fruit and vegetables consumption and obesity in Brazil. J Hum Growth Dev. 2016;26(2):243–52.
]
[
Carneiro F. Familial and hereditary gastric cancer: an overview. Best Pract Res Clin Gastroenterol. 2022 Jun–Aug;58–59:101800.
]
[
Wang SC, Yeu Y, Hammer STG, et al. Hispanic/Latino patients with gastric adenocarcinoma have distinct molecular profiles, including a high rate of germline CDH1 variants. Cancer Res. 2020 Jun 1;80(11):2114–24.
]
[
Bustos-Carpinteyro AR, Oliveira C, Sousa A, et al. CDH1 somatic alterations in Mexican patients with diffuse and mixed sporadic gastric cancer. BMC Cancer. 2019 Jan 14;19(1):69.
]
[
Chiurillo MA. Role of gene polymorphisms in gastric cancer and its precursor lesions: current knowledge and perspectives in Latin American countries. World J Gastroenterol. 2014;20(16):4503–15.
]
[
Cerrato-Izaguirre D, Chirino YI, García-Cuellar CM, et al. Mutational landscape of gastric adenocarcinoma in Latin America: a genetic approach for precision medicine. Genes Dis. 2021;9(4):928–40.
]
[
Champagne BM, Sebrié EM, Schargrodsky H, et al. Tobacco smoking in seven Latin American cities: the CARMELA study. Tob Control. 2010;19(6):457–62.
]
[
Díaz LA, Idalsoaga F, Fuentes-López E, et al. Impact of public health policies on alcohol-associated liver disease in Latin America: an ecological multinational study. Hepatology. 2021 Nov;74(5):2478–90.
]
[
Coelho LG, Coelho MC. Clinical management of Helicobacter pylori: the Latin American perspective. Dig Dis. 2014;32(3):302–9.
]
[
Vitiello GA, Hani L, Wang A, et al. Clinical presentation patterns and survival outcomes of Hispanic patients with gastric cancer. J Surg Res. 2021;268:606–15.
]
[
Karalis JD, Ju MR, Mansour JC, et al. The presentation of Hispanic gastric cancer patients varies by location of patient ancestry. J Surg Oncol. 2021;124(7):1051–9.
]
[
Calderillo-Ruíz G, Díaz-Romero MC, Carbajal-López B, et al. Latin American young patients with gastric adenocarcinoma: worst prognosis and outcomes. J Gastrointest Oncol. 2023;14(5):2018–27.
]
[
Mantilla MJ, Chaves JJ, Ochoa-Vera M, et al. Clinical characteristics of early-onset gastric cancer: a study in a Colombian population. Rev Gastroenterol Peru. 2023;43(3):236–41.
]
[
Bravo LE, Hernández Vargas JA, Collazos P, et al. Survival in stomach cancer: analysis of a national cancer information system and a population-based cancer registry in Colombia. Colomb Med (Cali). 2022;53(4):e2025126.
]
[
Hernandez-Felix JH, Meneses-Medina MI, Jiménez Meza MA, et al. Clinical presentation and delay to diagnosis and treatment in Mexican patients with gastric cancer. J Clin Oncol. 2024;42(3 Suppl):291.
]
[
Ruiz GC, Reynoso N, Diaz C, et al. Epidemiological data of patients with gastric cancer in Mexico. Ann Oncol. 2012;23(Suppl 9):ix251.
]
[
Freile B, van Schooten TS, Derks S, et al. Gastric cancer hospital-based registry: real-world gastric cancer data from Latin America and Europe. ESMO Gastrointest Oncol. 2024;6:100088.
]
[
Heise K, Bertran E, Andia ME, et al. Incidence and survival of stomach cancer in a high-risk population of Chile. World J Gastroenterol. 2009;15(15):1854–62.
]
[
Martínez-Galindo MG, Zamarripa-Dorsey F, Carmona-Castañeda A, et al. Histopathologic characteristics of gastric adenocarcinoma in Mexican patients: a 10-year experience at the Hospital Juárez of Mexico. Rev Gastroenterol Mex. 2015;80(1):21–6.
]
[
León AM, Hall WB, Lino LS, et al. Identification of prognostic factors for survival in patients with metastatic gastric adenocarcinoma in a Mexican population. Rev Gastroenterol Mex (Engl Ed). 2024;89(3):340–6.
]
[
Martínez-Ciarpaglini C, Barros R, Caballero C, et al. Comprehensive histopathological analysis of gastric cancer in European and Latin American populations reveals differences in PDL1, HER2, p53 and MUC6 expression. Gastric Cancer. 2025;28(2):160–73.
]
[
French K, Jayasekera M, Gage J, et al. Incidental finding of gastric signet ring cell carcinoma: a case report. Am J Gastroenterol. 2022;117(10 Suppl):e2273.
]
[
Maehara Y, Sakaguchi Y, Moriguchi S, et al. Signet ring cell carcinoma of the stomach. Cancer. 1992;69(7):1645–50.
]
[
Meneses Medina MI, Valenzuela AK, Hernandez-Felix JH, et al. Morbidity associated to advanced gastric cancer and its impact on overall survival. J Clin Oncol. 2025;38(4 Suppl):327.
]
[
Novick D, Mendez G, Carballido M, et al. Retrospective analysis of patients with locally advanced or metastatic gastric cancer in Argentina. Medwave. 2019;19(8):e7692.
]
[
Brito ABC, Felismino TC, E Silva DRM, et al. Survival trends in gastric cancer in Brazil: real-life data from a large cancer center. Ecancermedicalscience. 2024;18:1706.
]
[
Acuña S, Solís P, Oñate P, et al. Epidemiología del cáncer de estómago en un centro de referencia en Ecuador. Rev Med Vozandes. 2020;31(2):19–25.
]
[
McMillian N, Stein M, Ajani JA, et al. NCCN Clinical Practice Guidelines in Oncology: gastric cancer. Version 5.2024 [Internet]. National Comprehensive Cancer Network; 2024 [cited 2025 Oct 4]. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1434
]
[
Kujaruk M, Salanova R, Ruiz G, et al. Molecular and pathological features in patients with gastric cancer in Argentina: association between Epstein–Barr virus, MSI, PD-L1 expression and T-cells infiltration. Ann Oncol. 2019;30(Suppl 4):iv85.
]
[
Ramos MFKP, Pereira MA, de Mello ES, et al. Gastric cancer molecular classification based on immunohistochemistry and in situ hybridization: analysis in western patients after curative-intent surgery. World J Clin Oncol. 2021;12(8):688–701.
]
[
Ballen DF, Ojeda K, Gualdron A, et al. Real-world prevalence of biomarkers for treatment of advanced gastric cancer or gastroesophageal junction cancer in a cohort of Colombian patients [Internet]. Instituto Nacional de Cancerología; 2025 [cited 2025 Oct 4]. Available from: https://repositorio.cancer.gov.co/items/bdaa2e7c-f9ef-4adc-b3da-5d7cedd04920
]
[
González-Motta A, Negrete-Tobar G, Messa-Botero OA, et al. Prevalence of microsatellite instability in gastric and gastroesophageal junction cancer patients from a Latin American country. Gac Med Mex. 2024;160(4):393–8.
]
[
Dorantes-Heredia R, Motola-Kuba D, Escamilla-López I, et al. Prevalence of mismatch repair deficiency in advanced solid tumors (colorectal cancer and non-colorectal cancer) in one Mexican institution. J Pers Med. 2024;14(12):1152.
]
[
Diaz Romero MC, Miyagui-Adame SM, Calderillo Ruiz G, et al. Impact of DNA mismatch repair status on prognosis of patients with locally advanced gastric cancer in a Mexican population. J Clin Oncol. 2024;42(3 Suppl):408.
]
[
Cordova-Delgado M, Pinto MP, Retamal IN, et al. High proportion of potential candidates for immunotherapy in a Chilean cohort of gastric cancer patients: results of the FORCE1 study. Cancers (Basel). 2019;11(9):1275.
]
[
Tran-Minh ML, Lehmann-Che J, Lambert J, et al. Prevalence and prognosis of microsatellite instability in oesogastric adenocarcinoma: NORDICAP 16-01. Clin Res Hepatol Gastroenterol. 2021;45(4):101691.
]
[
Wu H, Ma W, Jiang C, et al. Heterogeneity and adjuvant therapeutic approaches in MSI-H/dMMR resectable gastric cancer: emerging trends in immunotherapy. Ann Surg Oncol. 2023;30(13):8572–87.
]
[
Randon G, Aoki Y, Cohen R, et al. Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade. J Immunother Cancer. 2023;11(6):e007104.
]
[
Talari FF, Bozorg A, Zeinali S, et al. Low incidence of microsatellite instability in gastric cancers and its association with clinicopathological characteristics: a comparative study. Sci Rep. 2023;13(1):21743.
]
[
Liu X, Liu J, Qiu H, et al. Prognostic significance of Epstein–Barr virus infection in gastric cancer: a meta-analysis. BMC Cancer. 2015;15:782.
]
[
Bai Y, Xie T, Wang Z, et al. Efficacy and predictive biomarkers of immunotherapy in Epstein–Barr virus-associated gastric cancer. J Immunother Cancer. 2022;10(3):e004080.
]
[
Xie T, Liu Y, Zhang Z, et al. Positive status of Epstein–Barr virus as a biomarker for gastric cancer immunotherapy: a prospective observational study. J Immunother. 2020;43(4):139–44.
]
[
de Lima MA, Ferreira MV, Barros MA, et al. Epstein–Barr virus-associated gastric carcinoma in Brazil: comparison between in situ hybridization and polymerase chain reaction detection. Braz J Microbiol. 2012;43(1):393–404.
]
[
Reyes ME, Zanella L, Riquelme I, et al. Exploring the genetic diversity of Epstein–Barr virus among patients with gastric cancer in southern Chile. Int J Mol Sci. 2023;24(14):11276.
]
[
Carrascal E, Koriyama C, Akiba S, Tamayo O, Itoh T, Eizuru Y, et al. Epstein–Barr virus-associated gastric carcinoma in Cali, Colombia. Oncol Rep. 2003;10(4):1059–62.
]
[
Vidal-Realpe A, Dueñas-Cuellar RA, Niño-Castaño VE, et al. Clinical and pathologic characteristics of gastric adenocarcinoma associated with Epstein–Barr virus in a region with a high incidence of gastric cancer in Colombia. Rev Gastroenterol Mex (Engl Ed). 2023;88(3):256–66.
]
[
Lange KJ, Siliézar MM, López NY, et al. Identificación del virus Epstein–Barr por hibridación in situ en pacientes con cáncer gástrico que asisten al Instituto de Cancerología (Incan) de Guatemala. Cienc Tecnol Salud. 2020;7(1):00–00.
]
[
Herrera-Goepfert R, Akiba S, Koriyama C, et al. Epstein–Barr virus-associated gastric carcinoma: evidence of age-dependence among a Mexican population. World J Gastroenterol. 2005 Oct 21;11(39):6096–103.
]
[
Beltrán Gárate B, Camara A, Kapsoli Sánchez MDC, et al. Impacto del virus Epstein–Barr en el cáncer gástrico en el Perú [Impact of the Epstein–Barr virus on gastric cancer in Peru]. Rev Gastroenterol Peru. 2019 Oct–Dec;39(4):319–22.
]
[
Cruz-Reyes C, Gamboa-Dominguez A. HER2 amplification in gastric cancer is a rare event restricted to the intestinal phenotype. Int J Surg Pathol. 2013;21(3):240–6.
]
[
Jung JE, Sérgio I, Ioshii O. Immunohistochemical assessment of HER2 expression in gastric cancer in a cohort of 118 Brazilian patients. J Bras Patol Med Lab. 2013;49(5):00–00.
]
[
Roa I, Slater J, Carvajal D, et al. Expresión y amplificación del gen HER2 en el cáncer gástrico avanzado [HER2 gene amplification and overexpression in advanced gastric cancer]. Rev Med Chil. 2013;141(11):1411–9.
]
[
Painemal C, Berrios M, Gallegos I, et al. Determination of the HER2 expression in Chilean patients with gastric cancer. Ann Oncol. 2012;23(Suppl 4):iv50.
]
[
López-Jiménez P, Tenorio-Torres JA, Villegas-Carlos F, et al. Prevalence of HER2 overexpression in gastric cancer at the National Medical Center 20 de Noviembre. Rev Esp Med Quir. 2018;23(1):5–9.
]
[
Alvarado-Cabrero I, Gil-Hernández S, Ruelas-Perea A, et al. Evaluación por inmunohistoquímica de la expresión del HER2 en cáncer gástrico: estudio clínico-patológico de 93 casos [Immunohistochemical assessment of HER2 expression in gastric cancer: a clinicopathologic study of 93 cases]. Cir Cir. 2017;85(6):504–9.
]
[
Diaz C, García-García E, Miyagui Adame S, et al. HER2 positive as the main biomarker for overall survival of advanced gastric adenocarcinoma: Latin American reality and challenges. Ann Oncol. 2023;34(Suppl 1):S67–8.
]
[
Beltrán Gárate B, Yabar Berrocal A. Expresión de HER2 en cáncer gástrico en el Perú [HER2 expression in gastric cancer in Peru]. Rev Gastroenterol Peru. 2010;30(4):324–7.
]
[
Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA international collaborative analysis. Ann Oncol. 2012;23(10):2656–62.
]
[
Matsusaka S, Nashimoto A, Nishikawa K, et al. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101). Gastric Cancer. 2016;19(3):839–51.
]
[
Huang D, Li ZS, Fan XS, et al. [HER2 status in gastric adenocarcinoma of Chinese: a multicenter study of 40,842 patients]. Zhonghua Bing Li Xue Za Zhi. 2018;47(11):822–6.
]
[
Seo KW, Jeon T, Kim S, et al. Epidemiologic study of human epidermal growth factor receptor 2 expression in advanced/metastatic gastric cancer: an assessment of HER2 status in tumor tissue samples of gastric and gastroesophageal junction cancer. J Gastric Cancer. 2017;17(1):52–62.
]
[
Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40.
]
[
Rha SY, Oh DY, Yañez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181–95.
]
[
Yamashita K, Iwatsuki M, Harada K, et al. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer. Gastric Cancer. 2020;23(1):95–104.
]
[
Pereira MA, Ramos MFKP, Dias AR, et al. Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer. Virchows Arch. 2021;478(6):1039–48.
]
[
Janjigian YY, Ajani JA, Moehler M, et al. First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial. J Clin Oncol. 2024;42(17):2012–20.
]
[
Braga-Neto MB, Carneiro JG, de Castro Barbosa AM, et al. Clinical characteristics of distal gastric cancer in young adults from Northeastern Brazil. BMC Cancer. 2018;18(1):131.
]
[
Dominguez RL, Montalvan-Sanchez EE, Norwood DA, et al. Population-based study of gastric cancer survival and associations in rural western Honduras. Cancer Epidemiol Biomarkers Prev. 2024;33(12):1578–85.
]
[
Diaz MDP, Icaza G, Nuñez L, et al. Gastric cancer mortality trends in the Southern Cone: disentangling age, period and cohort patterns in Argentina and Chile. Sci Rep. 2020;10(1):1526.
]
[
Santos E. Current approaches to gastric cancer in Peru and Mexico. Transl Gastroenterol Hepatol. 2017;2:55.
]
[
Müller B, García C, Sola JA, et al. Perioperative chemotherapy in locally advanced gastric cancer in Chile: from evidence to daily practice. Ecancermedicalscience. 2021;15:1244.
]
[
Verduzco-Aguirre HC, Meneses Medina MI, Valenzuela AK, et al. Treatment modalities and oncological outcomes in Mexican patients with localized gastric cancer. J Clin Oncol. 2020;38(4 Suppl):319.
]
[
Valenzuela AK, Meneses Medina MI, Camargo VR, et al. Treatment modalities and oncological outcomes in a cohort of patients with advanced gastric cancer in Mexico. J Clin Oncol. 2019;37(15 Suppl):e15590.
]
[
Shitara K, Ajani JA, Moehler M, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603(7903):942–8.
]
[
Chao J, Fuchs CS, Shitara K, et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol. 2021;7(6):895–902.
]
[
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.
]
[
Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402(10418):2197–208.
]
[
Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133–41.
]
[
Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655–68.
]
[
Wainberg ZA, Enzinger PC, Kang YK, et al. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022;23(11):1430–40.
]
[
Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–9.
]
[
Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35.
]
[
Drigo JM, Castillo C, Wever W, et al. Endoscopic ultrasound practice survey in Latin America. Endosc Ultrasound. 2013;2(4):208–18.
]
[
Durán CE, Cañás M, Urtasun M, et al. Potential negative impact of reputed regulators’ decisions on the approval status of new cancer drugs in Latin American countries: a descriptive analysis. PLoS One. 2021;16(7):e0254585.
]
[
Werutsky G, Barrios CH, Cardona AF, et al. Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean. Lancet Oncol. 2021;22(11):e488–500.
]
[
Acevedo AM, Gómez A, Becerra HA, et al. Distribution and trends of hematology and oncology research in Latin America: a decade of uncertainty. Cancer. 2014;120(8):1237–45.
]
[
Arai RJ, Guindalini RSC, Llera AS, et al. Personalizing precision oncology clinical trials in Latin America: an expert panel on challenges and opportunities. Oncologist. 2019;24(8):e709–19.
]
[
da Silva RE, Amato AA, Guilhem DB, et al. International clinical trials in Latin American and Caribbean countries: research and development to meet local health needs. Front Pharmacol. 2018;8:961.
]